Jently review

Jently’s sermorelin and NAD⁺ injection and nasal pages each show $199 for one month, $477 for three, $834 for six or $1,428 for twelve months. The $119 monthly equivalent is the annual prepay tier, not a month-to-month debit. Jently facilitates telehealth, MD Integrations supplies clinician access, and Precision Compounding Pharmacy is named as a compounder. The card is charged only after clinician approval, with a narrow refund window.

Jently, LLC is a New York telehealth facilitator. Licensed clinicians are accessed through the MD Integrations network, while compounded medications are prepared by third-party pharmacies including Precision Compounding Pharmacy in Bellmore. Its catalog includes injection and nasal options for both sermorelin and NAD⁺. Product cards show one-, three-, six- and twelve-month purchases; no comprehensive product-by-state eligibility list is published.

Fully online with one-, three-, six- and twelve-month plan purchases, prescribed through MD Integrations — a third-party network shared across many telehealth brands, which is a standard structure and worth understanding rather than assuming. It means the clinician reviewing your file is not employed by the brand you are buying from; the brand names the network, which is the disclosure that matters. Naming the operating LLC, its addresses, the governing law and the arbitration seat is a solid identity disclosure. The commercial terms are stated plainly and are worth reading before you subscribe: the subscription can be canceled at any time, your card details are collected during the questionnaire but "actual payment is processed only after provider approval", refund requests must be made within 24 hours of ordering and before a prescription is issued, and there is no refund once a consultation has been completed or a prescription dispensed. That last clause is the one to weigh, because the decision point is approval, not delivery. Not published: any state list — the site says only that providers are licensed in your state — so eligibility is confirmed during intake. The footer shows a LegitScript seal linking to LegitScript's checker for its site. There is no lab work in the default path.

For sermorelin injection, sermorelin nasal spray, NAD⁺ injection and NAD⁺ nasal spray, the published tiers are $199 for one month, $477 upfront for three months ($159/month equivalent), $834 upfront for six ($139/month equivalent) and $1,428 upfront for twelve ($119/month equivalent). The annual equivalent does not mean a $119 monthly charge. The cards do not establish whether longer plans ship in stages or auto-renew. Product pages state free cold-chain shipping. Jently collects card details at intake but says payment is processed only after clinician approval. Refund requests must arrive within 24 hours of ordering and before prescription issuance or shipment; the policy also excludes refunds after a completed consultation or dispensing. Confirm the selected term, shipment cadence and renewal before approval.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Jently states its products are compounded by third-party, state-licensed pharmacies and names one of them, Precision Compounding Pharmacy in Bellmore, New York, though it does not say whether that pharmacy fills every product. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are, so a named pharmacy is worth looking up. On the evidence, offering a nasal-spray route alongside an injection for both sermorelin and NAD⁺ is a convenience choice, not an evidence one, and neither route has data the other lacks. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism whose long-term human outcome data stays thin, with no controlled trial demonstrating the body-composition, recovery or anti-aging results it is marketed for. Injected and intranasal NAD⁺ have no controlled human outcome trials; the single human intravenous study was a pharmacokinetic pilot finding infused NAD⁺ clears from plasma quickly, and the forms with human trial data are the oral precursors NR and NMN, which raise blood NAD⁺ — a biomarker rather than a benefit. Injectable glutathione has essentially no controlled human outcome evidence. Individual results vary.